Integra Therapeutics
Integra Therapeutics54About
What does Integra Therapeutics do?
Integra Therapeutics is a biotechnology company focused on developing innovative gene writing tools to enhance the safety, precision, and efficacy of advanced therapies. Their lead technology, FiCAT, combines CRISPR precision with the efficiency of viral integrases and transposases to enable programmable delivery of large DNA sequences, aiming to overcome key limitations in gene therapy for genetic, oncological, and autoimmune diseases.
What is Integra Therapeutics's revenue?
StartupHub estimates Integra Therapeutics's annual revenue at $5.4M (range $3.8M to $12.1M, 65% confidence), based on comparable companies in the sector.
What is Integra Therapeutics's valuation?
StartupHub estimates Integra Therapeutics's effective valuation at $538.8M (range $336.9M to $808.6M, 19% confidence), based on comparable companies in the sector.
How much funding has Integra Therapeutics raised?
Integra Therapeutics has raised a total of $135M in funding. The most recent round on record is Series A.
Where is Integra Therapeutics headquartered?
Integra Therapeutics is headquartered in Barcelona, Spain.
When was Integra Therapeutics founded?
Integra Therapeutics was founded in 2020.
What industry does Integra Therapeutics operate in?
Integra Therapeutics operates in Biotech, Gene Therapy, Gene Editing, CAR-T, Oncology, Autoimmune Diseases.
How many employees does Integra Therapeutics have?
Integra Therapeutics has approximately 24 people on record.
No comments yet. Be the first to share your take.